Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (April 2024)
24 slides from Avicanna's investor presentation, Apr 25, 2024
Slide 1: An International Biopharmaceutical Strategy
Q2 2024 An International Biopharmaceutical Strategy Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments TSX: AVCN OTCQX: AVCNF FS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently veri able at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable secu
Slide 3: Corporate Highlights
0.1 Corporate Highlights An International Medical and Biopharmaceutical Strategy Commercial Platform • 4 commercial stage business pillars • 30+ commercialized proprietary SKUs • First pharmaceutical marketing authorization (Trunerox) • Addressing a global market opportunity – 20+ countries • 2023 r
Slide 4: Timeline and Evolution
0.2 Timeline and Evolution 1 3 5 7 9 11 Launched of RHO Phyto First major supply Avicanna Inc. is R&D and pharmaceutical IPO on Toronto Stock into major Canadian agreement with Pharmaceutical incorporated and collaboration with the Exchange (TSX: AVCN) hosptials, initially with international partner
Slide 5: Commercial Business Pillars
1.0 Commercial Business Pillars 1.1 1.2 1.3 1.4 Medical Cannabis Medical Cannabis Care Pharmaceutical Active Pharmaceutical Products Platform* Products Ingredients *MyMedi.ca is operated by Northern Green Canada for the Canadian market
Slide 6: RHO Phyto
1.1 Transdermal Gel Oil Drops Capsules RHO Phyto Advanced Drug Delivery System Formulations Water-Soluble Infusers Sublingual Spray (CBD, THC, CBG) - for International Medical and Local Creams Tablets Wellness Market Segments Gummies © 2024 Avicanna Inc.
Slide 7: Canadian Commercialization Infrastructure
1.1.1 Canadian Commercialization Infrastructure Proprietary and Commercial SKUs Across 133 Commercial Listings* National Medical Channels Provincial Retail Channels 27 7 Proprietary Commercial SKUs National Medical Cannabis Across 4 Brands Portals O ering Avicanna Products Including MyMedi.ca 79 133
Slide 8: MyMedi.ca
1.2 MyMedi.ca A Complete Medical Cannabis Care Platform
Slide 9: MyMedi.ca Online Platform for Canadian Patients
1.2.1 MyMedi.ca Online Platform for Canadian Patients and the Medical Community • Evidence-driven medical cannabis formulary - with 200+ SKUs from over 35 brands • Pharmacist-led and bilingual patient support programs • Specialty care programs including compassionate pricing and veterans’ a airs • I
Slide 10: Medical Affairs, Education and Training
1.2.2 Medical Affairs, Education and Training Patients • Education on the potential bene ts and risks associated with medical cannabis • Pharmacist led dosing and product support • Harm reduction education and initiatives Health Care Providers • Training and product guidelines on dosing and titratio
Slide 11: Pharmaceutical Products and Pipeline
1.3 Pharmaceutical Products and Pipeline A Complete Medical Cannabis Platform
Slide 12: Trunerox 10% CBD Oral Solution
1.3.1 TruneroxTM 10% CBD Oral Solution Adjunctive treatment of seizures associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS) • Marketing Authorization Obtained in Colombia by INVIMA Q1 2024 • Expected commercialization in Colombia late 2024 with opportunities to expand into other S
Slide 13: Pharmaceutical Pipeline and Drug Candidates
1.3.2 Pharmaceutical Pipeline and Drug Candidates Designed to Address 5 Major Clinical Areas Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Management Depression Bullosa • Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage • Leveraging
Slide 14: Active Pharmaceutical Ingredients (Aureus Santa Marta)
1.4 Active Pharmaceutical Ingredients (Aureus Santa Marta™)
Slide 15: Active Pharmaceutical Ingredients (Aureus Santa Marta)
1.4.1 Active Pharmaceutical Ingredients (Aureus Santa Marta™) Avicanna’s Supply Chain Business Segment and Vertical integration Raw Material Business Unit and Brand • 3 international pharmaceutical marketing authorizations with Aureus API including Trunerox TM • Avicanna’s low cost and consistent su
Slide 16: Avicanna Around the World
1.5 Avicanna Around the World Global Operations and Exports - 20+ countries MyMedi.ca MEDICAL CANNABIS CARE TRUNEROXTM 16 © 2024 Avicanna Inc. 
Slide 17: Scientific Platform
2.0 Scienti c Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products fi
Slide 18: Established Scientific Platform
2.1 Established Scienti c Platform 30+ Proprietary 10+ Scientists Commercial Products Extensive Pharmaceutical Pipeline 7 Pending Patents 11 Canadian Government Research 100% Ownership of Grants Awarded Since 2020 All IP and Trade Secrets 018 © 2024 Avicanna Inc.  fi
Slide 19: World-Class Institutional Collaborations
2.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017 019 © 2024 Avicanna Inc. 
Slide 20: Financial Overview
3.0 Financial Overview AVICANNA"
Slide 21: Financial & Capital Overview
3.1 Financial & Capital Overview Highlights • 2023 revenue of $16.8M, growth of 314% from $4M in 2022 • $6.67M consolidated gross profit, an increase of more than 500% from 2022 • Northern American gross margins of 45% • $97M shares issued and outstanding* Revenue to Gross Profit 2021 – 2023 $18M TSX
Slide 22: Management and Board of Directors
3.2 Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Phillip Cardella Eileen McCormack Chief Financial O cer Independant Director Stephen Kim John McVicar Chief Legal O cer & General Counsel Independant Director Iva
Slide 23: Corporate Highlights
3.3 Corporate Highlights • De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines • Diversified - scalable and high margin revenue streams • Experienced management - proven track record since 2016 • Intellectual property powerhouse
Slide 24: Thank You
AVICANNA Thank You